Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix Announces Change to its Board of Directors

GlobeNewswire December 11, 2019

Reminder: Resverlogix to Hold Conference Call and Webcast on December 6th, 2019

GlobeNewswire December 5, 2019

Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

GlobeNewswire December 2, 2019

Resverlogix Announces Warrant Exercise Incentive Program

GlobeNewswire November 25, 2019

Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019

GlobeNewswire November 12, 2019

Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders

GlobeNewswire October 31, 2019

Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders

GlobeNewswire October 31, 2019

Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial

GlobeNewswire September 30, 2019

Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan

GlobeNewswire September 27, 2019

Resverlogix to Host BETonMACE Webcast and Conference Call

GlobeNewswire September 26, 2019

Toronto Stock Exchange Introduces the TSX30

Canada NewsWire September 26, 2019

Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association's Scientific Sessions 2019

GlobeNewswire September 23, 2019

Resverlogix Provides Update on BETonMACE Phase 3 Trial

GlobeNewswire September 16, 2019

Resverlogix Announces Annual and Special Meeting of Shareholders

GlobeNewswire August 22, 2019

Zenith Announces Annual and Special Meeting of Shareholders

GlobeNewswire August 22, 2019

Resverlogix to Present at the European Society of Cardiology's ESC Congress 2019

GlobeNewswire August 14, 2019

Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694

GlobeNewswire August 6, 2019

Resverlogix Announces Loan Reduction and Extension

GlobeNewswire August 2, 2019

Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics

GlobeNewswire July 15, 2019

Resverlogix's BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

GlobeNewswire July 8, 2019